11th European Forum for Qualified Person for Pharmacovigilance (QPPV) London, England, UK 4-5 October 2017

Description:
This year's objectives, as shown below, build on past successes and have been
shaped by valuable feedback provided by participants of the past nine meeting, plus
will celebrate a decade of QPPV and Regulator interaction through this Forum.

Over time, one of the key successes of the Forum has been the ability to secure
continuing support and involvement of key regulators. Sessions have been open and
interactive with attendees appreciating opportunities to raise challenging issues in
an informal environment. This 11th QPPV Forum aims to continue to attract such key
speakers and encourage open debate.

Booking: https://go.evvnt.com/138351-1

Time: 08:00 to 20:00

Price:
Member Early-Bird: EUR 1330,
Member Advance Rate: EUR 1430,
Member Industry: EUR 1530,
Non-member Industry: EUR 1685,
Member Government/Charitable/Non-profit/Academia: EUR 765,
Non-member Government/Charitable/Non-profit/Academia: EUR 920

Speakers: Vicki Edwards (EU QPPV and Head of Affiliate Vigilance Excellence, AbbVie), Margaret Walters (Director and Deputy EU QPPV, Merck Sharp and Dohme), Elspeth McIntosh (Director, Castle Pharmacovigilance), Doris Stenver (CMO, Danish Medicines Agency), Michael Richardson (Int. Head of GPVandE and EU QPPV, Bristol-Myers Squibb), Brian Edwards (Principal Consultant, PV and Drug Safety) NDA Regulatory Services, Winrich Rauschning (QPPV, BioLitec Pharma), Barbara De Bernardi (EU QPPV Deputy, Pfizer), Peter De Veene (Head Global Drug Safety and QPPV, Grunenthal)